Statement of Principles concerning retinal vascular occlusion (Reasonable Hypothesis) (No. 50 of 2020)

The instrument is structured around a small set of interlocking legal-medical concepts that determine how RVO claims are to be assessed.

Retinal vascular occlusion definition. The SOP defines RVO for claims purposes in s 7(2): obstruction to blood flow in either the retinal artery (or its branches) or the retinal vein (or its tributaries), leading to visual impairment, while excluding ischaemic optic neuropathy and ophthalmic artery occlusion. The instrument expressly treats the ICD‑10‑AM code H34 as an identifier but states that the statutory meaning is the textual definition in s 7(2) (s 7(3)-(4)).

Reasonable hypothesis threshold. The legal threshold the instrument addresses is the "reasonable hypothesis" standard used under the VEA and MRCA. Section 9 sets out that at least one enumerated factor must exist before a reasonable hypothesis may be said to have been raised connecting RVO or death from RVO with relevant service. The RMA states that its determination is founded on "sound medical‑scientific evidence" (s 8), which is the evidentiary premise for the list of factors.

Two causal scenarios: onset and worsening. The instrument distinguishes between clinical onset and clinical worsening of RVO. Items 9(1)-9(22) set factors tied to clinical onset; items 9(23)-9(45) set substantially parallel factors tied to clinical worsening. Section 10(2) limits the application of the worsening factors (9(23)-9(45)) to cases where the person’s RVO was suffered or contracted before or during (but did not arise out of) their relevant service, applying only to material contribution or aggravation. This split affects which parts of the list are used depending on timing of the disease relative to service.

Temporal windows and quantitative thresholds. Several factors in the lists have precise temporal or quantitative elements. Examples: smoking at least ten pack-years before clinical onset, and where smoking has permanently ceased, onset within ten years of cessation (s 9(1)); drug exposure within 72 hours before onset or worsening (s 9(18), 9(40)); ocular/orbital infection within 30 days before onset or worsening (s 9(15), 9(37)); direct external pressure to the eyeball for at least ten continuous minutes within 24 hours (s 9(16), 9(38)); blunt or penetrating injury or certain procedures within seven days (s 9(17), 9(39)). The Schedule 1 Dictionary then gives precise biomedical definitions such as BMI, chronic renal failure criteria (GFR <15 mL/min/1.73 m2 over three months, renal replacement therapy or chronic dialysis), and one pack-year calculations (Schedule 1).

Condition-specific factors. The instrument separates factors that are specific to retinal venous occlusion (RVO-venous) and retinal arterial occlusion (RVO-arterial). For example: open-angle glaucoma, angle-closure glaucoma, ocular hypertension, chronic renal failure, severe dehydration and obstructive sleep apnoea are listed for venous occlusion (s 9(21)); carotid artery disease, cardiac disease capable of giving rise to a retinal embolus, non-cardiac potential sources of retinal embolus, and recent intravascular or cardiac/carotid procedures are listed for arterial occlusion (s 9(22)). For worsening, the same condition-specific distinctions recur (s 9(43)-(44)).

Cross-application with other SOPs. Section 11 provides that if a listed factor refers to another injury or disease that has its own SOP, the factors in that other SOP apply in accordance with its terms. That creates a linked network of SOPs and means some factors referenced must be proved using the criteria of a separate SOP.

Death and terminal events. Section 7(5) specifies that RVO includes death from a terminal event or condition that was contributed to by a person’s RVO. The Schedule 1 defines "terminal event" to include pneumonia, respiratory failure, cardiac arrest, circulatory failure, and cessation of brain function.

Specified lists and examples. Several terms are supported by specified lists in the Dictionary: specified list of drugs (amphetamines, cannabis, intranasal cocaine, talc‑contaminated IV heroin, PDE5 inhibitors, testosterone supplementation, tranexamic acid), specified systemic arteritides (giant cell arteritis, polyarteritis nodosa, Takayasu arteritis, thromboangiitis obliterans) and specified vasculopathies (fibromuscular dysplasia, Moyamoya disease, Sneddon syndrome) (Schedule 1).

Exclusion and scope limitations. The SOP expressly excludes ischaemic optic neuropathy and ophthalmic artery occlusion (s 7(2)(b)). It also places constraints on the use of worsening factors,these apply only to material contribution or aggravation where the condition pre-existed or was contracted before or during service but did not arise out of service (s 10(2)). The instrument uses precise definitions rather than free-floating clinical descriptors; these definitions determine eligibility for the "reasonable hypothesis" being raised.

Taken together, the main concepts are a statutory definition of the condition for claims, an enumerated minimum-factor test to satisfy the reasonable hypothesis threshold, temporal and quantitative tests for many factors, condition-specific risk or causal factors, and cross-references to other SOPs and ICD coding for classification but not definition.

Primary affected persons. The SOP directly affects persons claiming an entitlement under the VEA or MRCA where retinal vascular occlusion or death from retinal vascular occlusion is alleged to be connected to relevant service. Section 5 states the instrument "applies to a claim to which section 120A of the VEA or section 338 of the MRCA applies." Those statutory provisions create the claims framework; this SOP supplies the medical rules decision-makers must apply when considering the reasonable hypothesis limb of the causation assessment.

Veterans and members. The SOP refers to "veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA" in s 8 as the classes of persons for whom the RMA considered the medical-scientific evidence. Practically, that means serving or former members of the Australian Defence Force, in whatever category is captured by the statutory definitions of "relevant service" in Schedule 1 (operational service, peacekeeping service, hazardous service, British nuclear test defence service; under MRCA, warlike and non-warlike service) are affected parties (Schedule 1).

Decision-makers and administrative actors. The instrument constrains and directs the administrative decision-making of the Department and the Medical Officer role who assess claims under the VEA and MRCA. While the SOP is made by the RMA (s 3), the SOP’s lists and definitions are the medical-scientific predicate that decision-makers must apply when assessing whether a reasonable hypothesis exists in respect of RVO. The instrument also affects clinicians who prepare medical reports for claims, because the reports must engage with the factors and definitions used in the SOP if they are to establish the minimum factor(s) required by s 9.

Legal practitioners, advocates and assessors. Lawyers, advocates, claims officers, and medical assessors advising claimants or decision-makers must use the SOP to frame causation evidence and to decide which elements of medical history and objective testing to obtain. The instrument’s specific thresholds (eg pack-year calculations, BMI, GFR cut-offs, timing windows for procedures or exposures) directly inform what documentary and clinical evidence will be persuasive.

Healthcare providers and hospitals. Providers who have records showing exposures, surgical procedures, anaesthesia types, drug administration logs, weight and height data, laboratory lipid values, GFR measures, dialysis records, or records of infection episodes are materially affected. The SOP requires precise clinical data; its temporal windows mean that hospital procedure notes and medication administration records are evidentiary inputs in claims.

Interconnected SOPs. Parties connected to other SOPs are also affected indirectly by this instrument. Section 11 states that if a factor in this SOP refers to an injury or disease covered by another SOP, the factors in that other SOP apply. That produces an administrative dependence: a claimant alleging a factor that is itself covered by another SOP must satisfy that other SOP’s requirements as part of proving the factor here.

Those not directly affected. The instrument does not create offences, regulatory duties for the general public, or private civil-law obligations. It is an administrative instrument for the evaluation of entitlement claims; it does not itself confer benefits or penalties beyond informing statutory decision-making under the VEA and MRCA (s 3, s 5). It also does not create a private cause of action in negligence or otherwise.

In short, the SOP materially affects claimants with alleged RVO linked to relevant service, the medical and administrative assessors and advocates who prepare or adjudicate claims, and healthcare providers whose records supply the necessary medical evidence. It links to other SOPs, so parties dealing with cross-referenced diseases must coordinate evidentiary strategies across instruments.

Statutory and administrative duties. The instrument itself is made by the Repatriation Medical Authority under s 196B(2) of the VEA (s 3). Its key administrative effect is to supply the medical framework decision-makers must use when applying the "reasonable hypothesis" test for claims under s 120A of the VEA or s 338 of the MRCA (s 5). The SOP does not set out the full decision-making procedure, but it places duties on decision-makers to check the enumerated factors in s 9 and the Schedule 1 definitions when deciding whether the minimum factual threshold for a reasonable hypothesis is met. Put simply, a decision-maker assessing a claim for RVO must determine whether at least one of the listed factors exists in relation to the claimant’s clinical onset or worsening, and whether the factor is related to relevant service per s 10(1).

Claimant rights and evidentiary expectations. The instrument does not specify procedural rights such as review or appeal; those rights are contained in the VEA and MRCA regimes. Nevertheless, the SOP materially affects claimants’ evidentiary rights and expectations because it sets what medical circumstances count as a minimum basis for raising a reasonable hypothesis (s 9). Claimants have the right, under the broader claims system, to present medical evidence. The SOP makes clear what kinds of medical facts will be accepted as meeting the minimum-factor test: documented smoking history (pack-years), diagnoses of hypertension, diabetes mellitus, dyslipidaemia evidenced by lab thresholds or lipid-lowering therapy, BMI-based obesity, specific infections, recent procedures and injuries within stipulated windows, documented exposure to specified drugs, and so on (s 9; Schedule 1). Where a listed factor refers to another SOP, the claimant must meet the other SOP’s terms (s 11).

Relationship-to-service duty. Section 10 imposes an essential linkage duty: the existence of any factor in s 9 "must be related to the relevant service rendered by the person" (s 10(1)). That means proof of a factor alone is not sufficient; the factor must be connected to service in the manner the broader statutory scheme requires. For the subset of factors in s 9(23)-9(45) (the worsening list), s 10(2) narrows their use: those factors apply only to material contribution to, or aggravation of, RVO where the RVO was suffered or contracted before or during (but did not arise out of) the person’s relevant service.

Cross-application duty. Section 11 creates an administrative duty to consult and apply other SOPs where factors refer to diseases or injuries separately covered. If a listed factor is itself an injury or disease for which there is an SOP, the decision-maker must apply the factors in that other SOP according to its terms. That creates a duty of cross-referencing and consistency across instruments.

No penal or criminal duties. The SOP contains no penalties, fines, or criminal sanctions and does not create directly enforceable obligations on private actors. Its duties are administrative and evidentiary, imposed on decision-makers and indirectly on claimants and medical reporters.

Practical evidentiary duties. Although the SOP does not state what constitutes prima facie evidence, its precise thresholds create practical duties for claimants and clinicians to supply relevant documentary and clinical proof: smoking history quantified into pack-years as defined (Schedule 1); BMI calculation and serial weight/height measurements; laboratory lipid values meeting the dyslipidaemia thresholds set in the Schedule; GFR documentation or dialysis records for chronic renal failure; procedure notes and timing for recent intravascular or cardiac procedures; medication administration records for the specified drugs list and contraceptive pill duration; and documentation supporting a diagnosis of obstructive sleep apnoea, migraine, carotid artery disease, or other listed conditions. Section 9(45) also includes "inability to obtain appropriate clinical management" as a factor, which places an evidentiary duty on claimants to document the nature and timing of the inability to access care.

Limitations and decision-maker discretion. The RMA records that the SOP is based on sound medical‑scientific evidence (s 8), but the instrument itself does not fix how decision-makers must weigh competing medical opinions, nor does it define the procedural steps for medical examination or review. Those procedural aspects and rights of review exist in the parent Acts and administrative law, not in the SOP. What the SOP does is set a categorical floor: without at least one listed factor (properly related to relevant service), a reasonable hypothesis cannot be said to exist (s 9).

In summary, the SOP imposes duties on decision-makers to apply the enumerated factors and definitions when testing the reasonable hypothesis threshold; it imposes practical evidentiary expectations on claimants and clinicians; and it cross-references other SOPs, creating duties of coordination. It does not create criminal or civil penalties.

No direct offences or penalties. The Statement of Principles instrument contains no provisions creating criminal offences, civil penalties, or regulatory sanctioning mechanisms. It is an administrative determination made under subsection 196B(2) of the VEA (s 3) that sets medical criteria for assessing entitlement claims; the instrument itself does not specify enforcement sanctions or penalties for non-compliance by private parties.

Enforcement mechanism is administrative application. The instrument is applied within statutory decision-making frameworks of the VEA and MRCA. Its "enforcement" occurs through its mandatory use by decision-makers assessing whether a reasonable hypothesis exists in a claims context. The SOP establishes medical thresholds and temporal windows that adjudicators must consider when applying the statutory causation tests under s 120A of the VEA and s 338 of the MRCA (s 5). If decision-makers do not apply an SOP correctly, the remedy is administrative (internal review, merits review, or judicial review) under those statutes and general administrative law, not a penalty imposed by the SOP itself.

Evidentiary consequences. Failure by a claimant to provide evidence satisfying at least one of the factors listed in s 9 will have the practical consequence of the decision-maker being unable to conclude that a reasonable hypothesis has been raised. That consequence can lead to refusal of an entitlement claim and therefore an indirect adverse outcome for the claimant. The instrument does not prescribe appeal rights, but appeal and review mechanisms are contained in the VEA and MRCA. The SOP therefore operates as an evidentiary and determinative instrument rather than an enforcement statute.

Accountability and administrative review. The SOP is made by the RMA (s 3) and recorded as being based on "sound medical‑scientific evidence" (s 8). Where stakeholders dispute the RMA’s application of the SOP or its content, the pathways for challenge are the statutory review and dispute mechanisms applicable to RMA determinations and administrative decisions under the VEA and MRCA and judicial review channels, none of which are contained in this SOP text. The instrument’s compilation endnotes record the dates and amending instruments, which is relevant to challenge or to determining which version applied to a particular claim (endnotes, legislation history).

Recordkeeping and compliance risk. The practical enforcement pressure falls on the administrative process: decision-makers will require records to show whether a factor existed and was related to relevant service (s 10). If adequate medical records are not produced, the claimant risks denial. The instrument thus creates a compliance environment where the lack of documentary evidence has an enforcement-like effect in the form of adverse claim outcomes, but that is a consequence of administrative decision-making rather than a legal penalty prescribed in the SOP.

In sum, the SOP contains no penal provisions; its enforcement is administrative and evidentiary, operating through the claims assessment process under the VEA and MRCA. The principal "sanction" for non-compliance with the evidentiary expectations the SOP creates is denial of a claim, administered through the broader statutory regime.

Parent statutes and authority. The SOP is a subordinate instrument under the VEA. Section 3 states it is made under subsection 196B(2) of the VEA. Section 5 specifies that it applies to claims to which section 120A of the VEA or section 338 of the MRCA applies. Therefore, the SOP functions within and is subordinate to the VEA and MRCA claim frameworks. It does not alter statutory entitlement thresholds but supplies the RMA’s medical-scientific criteria for the reasonable hypothesis limb of causation assessments used by decision-makers under those Acts (s 5, s 8).

Cross-references to other SOPs. Section 11 creates a specific point of interaction with other Statements of Principles: where a factor in this SOP refers to an injury or disease that is the subject of another SOP, that other SOP’s factors apply "in accordance with the terms of that Statement of Principles as in force from time to time." That means a claimant who relies, for example, on a factor that is itself a separate medical condition must meet the other SOP’s tests. The SOP therefore forms part of an interconnected network of RMA instruments. Decision-makers must consult the current versions of those other SOPs when evaluating linked factors.

Use of ICD coding. Section 7(3)-(4) references ICD‑10‑AM code H34 as the usual classification code for retinal vascular occlusion but emphasises that in applying this SOP the statutory definition in s 7(2) controls. Thus, the SOP interacts with standard international disease classifications for identification but asserts a legal definition as primary for claims purposes. The instrument also specifies the edition and effective date of the ICD‑10‑AM (Tenth Edition, effective 1 July 2017) as the coded reference (s 7(4)).

Overlap with clinical standards and professional practice. The SOP’s definitions and thresholds (for example BMI for obesity, lipid thresholds for dyslipidaemia, GFR cut-offs for chronic renal failure, temporal windows for exposure to drugs and procedures) map onto clinical diagnostic criteria but adapt them for claims assessment. The SOP therefore intersects with clinical guidelines and diagnostic standards: treating clinicians’ diagnoses and records are the evidence that will be assessed against the SOP’s defined thresholds. The SOP does not override clinical practice but uses clinical data in a legally prescriptive way.

Interaction with evidentiary and procedural law. While the SOP sets the medical criteria, it does not prescribe the procedural law for how claims are processed, contested, or reviewed. Those procedural aspects are governed by the VEA, MRCA and administrative law. For example, if a claimant disputes a decision that relied on the SOP, the appeal, review and judicial review mechanisms in the parent statutes and general administrative law apply; the SOP is one element subject to scrutiny in those reviews.

Amendment mechanics and commencement. The compilation endnotes record that the instrument was made on 29 June 2020 and commenced 27 July 2020, and that it was amended by a definition-of-one-pack-year determination in 2022, which commenced 19 September 2022 (endnote 3). This interaction shows how subordinate instruments can be varied by later RMA determinations and how timing of amendments matters for which version applies to a given claim.

Limitations and exclusions relative to other laws. The SOP expressly excludes ischaemic optic neuropathy and ophthalmic artery occlusion from its definition of RVO (s 7(2)(b)). Where a claimant’s pathology is one of those excluded conditions, the SOP is not applicable; another SOP or legal pathway would be relevant. Similarly, factors that require proof of another disease covered by a separate SOP require the decision-maker to apply that SOP’s terms (s 11).

In short, the SOP is an administrative instrument subordinate to the VEA and MRCA; it interfaces with other SOPs through s 11, uses ICD coding for classification but provides a statutory definition, interacts with clinical diagnostic standards by converting clinical metrics into legally usable thresholds, and is subject to amendment and compilation history recorded in the endnotes.

Dates and instruments. The compilation endnotes record the legislative history of this SOP. The Statement of Principles concerning retinal vascular occlusion (Reasonable Hypothesis) (No. 50 of 2020) was registered on 29 June 2020 and commenced on 27 July 2020 (Endnote 3). It was subsequently amended by the Veterans' Entitlements (Statements of Principles,definition of "one pack-year") Amendment Determination 2022 (No. 94 of 2022), which was registered 26 August 2022 and commenced on 19 September 2022 (Endnote 3).

Nature of the 2022 amendment. The amendment made in 2022 concerned the Schedule 1 Dictionary definition of "one pack‑year" and related notes in subsections 9(1) and 9(23) (Endnote 4). The amendment replaces or clarifies the quantitative conversion rules for different tobacco products and provides the equivalence of one gram of pipe tobacco, cigars or combinations to one cigarette for pack-year calculations, and gives the grams-equivalent total for 20 cigarettes per day for a year (7,300 grams). The amendment history table (Endnote 4) records that the Schedule 1 Dictionary’s "one pack-year" provision was revised by No. 94 of 2022.

Compilation notes and effective text. This document is a compilation current to 19 September 2022, meaning it shows the text of the SOP as amended up to the 2022 pack-year amendment (Compilation No. 1). The endnotes explain that uncommenced amendments are not shown in the text and that modifications may be effected by other laws without textual amendment in this compilation (Compilation notes at top and Endnote 1). Users must check the Legislation Register for any subsequent amending instruments or uncommenced amendments.

Amendment annotation. The amendment history grid in Endnote 4 records specific provisions affected: Section 2 and Section 4 were amended as a consequence of Legislation Act provisions (rep LA s 48D and rep LA s 48C respectively); the notes to subsections 9(1) and 9(23) and the Schedule 1 definition of one pack-year were revised by the 2022 instrument (rs No. 94 of 2022). The compilation records these amendments with the usual annotation that identifies which instrument made the change and when it commenced.

Implication for claims spanning amendments. Because SOPs are used in assessing claims, the commencement dates of amendments matter. The 2022 amendment took effect on 19 September 2022 (Endnote 3). Decision-makers assessing claims with clinical onsets or evidence submitted across amendment dates will need to determine which version of the SOP applied to the relevant claim time; the parent statutes and administrative practice require that the correct version be applied according to commencement and transitional rules where necessary. The compilation warns that uncommenced amendments are not shown and provides links to the Legislation Register for up-to-date details.

No subsequent amending laws recorded in compilation. As of the compilation date, the legislation history shows only the original SOP (No. 50 of 2020) and the 2022 amendment (No. 94 of 2022) (Endnote 3). The compilation’s Endnote 4 lists the precise provisions affected and references the relevant amending instruments.

Record of misdescribed amendments. The endnotes contain the usual explanation about misdescribed amendments and how they are annotated, but there is no record here of maldescribed or unincorporated amendments affecting this SOP in the compilation’s amendment history table (Endnote 4).

Practical takeaway on amendment risk. Users must check the Legislation Register and the RMA’s series page for any later amendments or uncommenced variations that might alter definitions (for example, the definition of one pack-year or thresholds used in the Schedule) because such amendments can change eligibility and evidentiary requirements for claims. The compilation makes explicit which amendments are incorporated and their commencement dates (Endnote 3, Endnote 4).

No judicial decisions recorded in the instrument. The compiled text of this Statement of Principles does not name any judicial decisions, nor does it include a litigation history. The SOP’s endnotes and legislation history record administrative actions and amending instruments but do not record court cases. The instrument itself is an administrative medical determination, and the compilation does not include or cite any legal proceedings that have interpreted this specific SOP.

Where to look for litigation or interpretive authority. If parties wish to locate litigation that addresses the application of this SOP, they must search case law databases and administrative decisions under the VEA and MRCA where adjudicators, tribunals, or courts have considered retinal vascular occlusion claims and the application of this or earlier SOPs. The compilation provides the authoritative text and amendment history as of 19 September 2022 but contains no record of cases deciding issues of interpretation or application.

Implications of absence of recorded litigation. The absence of litigation recorded in this compiled instrument means that administrative practice and the text of the SOP itself will primarily guide claim assessment until appellate bodies or courts produce binding interpretations. Decision-makers and practitioners should therefore pay close attention to the SOP’s precise language, the Schedule 1 definitions, and the cross-application clause in s 11 when preparing and deciding claims.

Judicial avenues remain available. Even though the SOP contains no litigation history, its application in decisions under the VEA and MRCA is subject to the external legal processes available to claimants, including internal review, merits review and judicial review. Challenges to administrative decisions that apply this SOP would proceed under the statutory review mechanisms in the VEA and MRCA and the administrative law framework, but those mechanisms and their caselaw are not documented within the SOP text.

Recommendation if litigation is intended. Practitioners seeking precedential interpretations should track Administrative Appeals Tribunal decisions, Federal Court or Federal Circuit Court decisions, and any VEA-specific review tribunal decisions that consider RVO in the context of this SOP. The compilation itself does not supply such authorities.

Temporal and causal complexity. The SOP differentiates factors for the clinical onset of RVO (s 9(1)-(22)) from those relevant to clinical worsening (s 9(23)-(45)). Practitioners must not conflate these lists. Moreover, s 10(2) restricts the worsening list to situations where the person’s RVO was suffered or contracted before or during (but did not arise out of) relevant service, and where the factor is said to materially contribute to or aggravate the RVO. That creates a two-tiered temporal constraint: whether the condition pre-existed service and whether the factor is a material contributor to aggravation. Failure to establish those temporal relations will make entries in the worsening list inapplicable.

Pack-year calculations and the 2022 amendment. The definition of one pack-year in Schedule 1 is technical and was subject to amendment in 2022 (Endnote 4). The conversion rules equate 20 cigarettes per day for one year to 7,300 grams of tobacco by weight and equate one gram of pipe tobacco or cigars to one cigarette (Schedule 1). Practitioners should ensure pack‑year calculations are prepared in accordance with the current Schedule 1 text; older medical histories that merely state "smoked heavily" without quantified pack‑years risk being insufficient under s 9(1) and 9(23). Also note the smoking-cessation window: if smoking has permanently ceased, onset or worsening must occur within ten years of cessation (s 9(1), 9(23)).

Precise time windows for exposures. Several factors have short and very specific temporal windows: drug exposure within 72 hours before clinical onset or worsening (s 9(18), 9(40)); direct external ocular pressure for at least ten continuous minutes within 24 hours before onset or worsening (s 9(16), 9(38)); ocular or orbital infection within 30 days before onset or worsening (s 9(15), 9(37)); blunt or penetrating injury or specified procedures within seven days (s 9(17), 9(39)). Records must document exact timing. Casual references to "recent surgery" or "recent drug use" will not automatically satisfy these time-limited criteria.

Condition-specific distinctions and diagnostic precision. The SOP separates venous and arterial occlusion risk factors (s 9(21)-(22) and s 9(43)-(44)). Claimants and clinicians must be clear which anatomical subtype of RVO is in issue and provide objective evidence accordingly. For example, carotid artery disease and cardiac embolic sources are listed for arterial occlusion (s 9(22)); open-angle glaucoma and chronic renal failure are listed for venous occlusion (s 9(21)). Misclassifying the occlusion type or failing to document the subtype will complicate assessment.

Exclusions from the definition. RVO in the SOP explicitly excludes ischaemic optic neuropathy and ophthalmic artery occlusion (s 7(2)(b)). If a claimant’s diagnosis is one of these excluded conditions, the SOP will not assist; a different SOP or legal avenue may be required.

Cross-SOP dependencies. If a listed factor is itself an injury or disease covered by another SOP, s 11 requires application of that other SOP’s factors. Practically, this means a claimant citing, for example, "hypertension" or "diabetes mellitus" may also invoke other SOPs about those conditions. Decision-makers will require proof that satisfies both the RVO SOP and the referenced SOP, as applicable.

Ambiguities in broad factors. Item 9(45) lists "inability to obtain appropriate clinical management for retinal vascular occlusion" as a factor. That is a broad and potentially subjective criterion. The Schedule does not define "appropriate clinical management." Practitioners should supply contemporaneous records showing attempts to access care, referrals, wait times, and urgent-care constraints to make this factor concrete in adjudication.

Specified drugs and modes of administration. The specified list of drugs in Schedule 1 includes intranasal cocaine, intravenous heroin contaminated with talc, and PDE5 inhibitors among others. The SOP is precise about modes of administration for some items (eg intranasal cocaine, intravenous heroin) (Schedule 1). A medical record that lists "cocaine use" without specifying route may require further clinical history to align with the list.

Objective thresholds required. Many factors require objective evidence. Dyslipidaemia is defined by specific lab thresholds (total cholesterol >5.5 mmol/L, LDL >4.0 mmol/L, HDL <1.0 mmol/L, triglycerides ≥2.0 mmol/L) or the regular administration of lipid-lowering drugs (Schedule 1). Chronic renal failure requires GFR <15 mL/min/1.73 m2 for at least three months, renal replacement therapy or chronic dialysis (Schedule 1). Practitioners should not rely on informal clinician notes alone; laboratory and treatment records are necessary.

Death and terminal event causation. Section 7(5) treats death from RVO as death from a terminal event or condition that was contributed to by the person's RVO. The Schedule defines "terminal event" with specific examples such as pneumonia, respiratory failure, cardiac arrest and circulatory failure (Schedule 1). A post-mortem or treating clinician’s opinion linking RVO to the terminal event will be necessary to invoke this provision.

Evidence of temporal relationships to service. Section 10(1) requires that the existence of any factor be "related to the relevant service rendered by the person." It is insufficient to show the factor exists; the claimant must show how it is connected to the person’s service. Proving that link may require service medical records, deployment histories, in-service exposures, or contemporaneous clinical notes that tie onset or exacerbation to a particular period of service.

No direct procedural guidance. The SOP sets medical criteria but does not provide procedural rules for how evidence is to be admitted, how conflicts between medical opinions are to be resolved, or how decision-makers should weigh multiple competing factors. Those procedural and evidentiary questions must be handled under the parent Acts and administrative law.

In summary, the gotchas are the precise temporal and quantitative thresholds, the necessity of matching subtype (arterial vs venous) to the correct factor list, the cross-application requirement to other SOPs, the narrowness of specified drug routes and procedural timing, the definitional exclusions, and the evidentiary burden to link factors to relevant service. Practitioners must plan evidence-gathering accordingly.

Evidence strategy and documentation. Prepare a targeted evidentiary bundle that maps directly to the SOP’s enumerated factors and Schedule 1 definitions. For each claimed factor in s 9, assemble contemporaneous or retrospective medical records, diagnostic test results, procedure notes, medication administration records, surgical and anaesthetic notes, incident reports, and service medical records that establish timing, diagnosis, and treatment. For example:

• Smoking history: calculate pack‑years using Schedule 1 rules; document dates of cessation if applicable to verify the ten‑year cessation window in s 9(1) and 9(23).
• Obesity: provide weight and height measurements at or near the clinical onset/worsening to calculate BMI and show BMI ≥30 (Schedule 1).
• Dyslipidaemia: include lipid panels showing thresholds stated in Schedule 1 or records of prescribed and regularly administered lipid-lowering therapy.
• Chronic renal failure: include GFR measures over at least three months, documentation of renal replacement therapy or dialysis logs (Schedule 1).
• Drug exposure: produce medication records or credible contemporaneous notes indicating use of specified drugs within 72 hours prior to the clinical onset or worsening (s 9(18), 9(40); Schedule 1 specified list of drugs).
• Procedures and injuries: supply operation notes, interventional radiology or catheterisation logs, and procedure dates to satisfy seven-day windows for certain intravascular, cardiac or carotid procedures (s 9(22)(d); s 9(44)(d)).
• Ocular infections: include microbiology, ophthalmology notes and dates; ensure the 30-day window is demonstrated (s 9(15), 9(37)).
• External mechanical pressure: document positioning notes, surgical position records, device use and timing for direct external pressure that persisted at least ten minutes within 24 hours (s 9(16), 9(38)).

Establish timing relative to service. For any factor invoked, compile service records that establish the temporal relationship required by s 10(1). Where the factor is said to arise because of or during service, include deployment dates, in-service medical records, occupational exposure records, and any incident reports. For worsening factors under s 10(2), ensure that the RVO was suffered or contracted before or during service but did not arise out of the service; provide evidence to satisfy that prerequisite.

Address cross-SOP references proactively. If a factor invokes another injury or disease that has an SOP (for example, a listed arteritis or a defined disease such as hypertension that may have its own SOP), obtain and review that SOP and gather evidence that will satisfy both instruments. Section 11 requires application of the other SOP’s factors "as in force from time to time"; therefore, identify the correct version by commencement dates and present the necessary evidence accordingly.

Medical opinion framing. Commission qualified specialist medical reports that directly address the SOP’s elements. A specialist report should:

• State the diagnosed subtype of occlusion (retinal artery or retinal vein) and link the diagnosis to objective testing.
• Explicitly address each SOP factor relied upon, citing the Schedule 1 definitions and the relevant subsection in s 9.
• For temporal elements, provide opinion on timing and plausibility of causation within the specified windows (eg 72 hours for drug exposure).
• For worsening claims, explain material contribution or aggravation and explicitly relate the aggravation to service, addressing s 10(2).
• Where death is alleged to have been contributed to by RVO, state how the RVO contributed to the terminal event listed in Schedule 1 and explain the causal sequence consistent with s 7(5).

Address ambiguous or broad criteria. For factors such as "inability to obtain appropriate clinical management" (s 9(45)), document attempts to obtain care, referral and wait lists, denial or delay of treatment, geographic or logistical barriers, and contemporaneous clinical deterioration. Provide evidence that the lack of management was relevant to onset or worsening.

Quantify and convert where required. Apply Schedule 1’s precise conversions for pack-years and BMI calculations; show the arithmetic used. For tobacco products other than cigarettes, attach conversion computations showing equivalence to the "one pack‑year" definition as amended in 2022.

Sequence records and indexing. Produce a chronological index mapping each record to the particular subsection of s 9 it evidences. This reduces administrative friction and helps decision-makers see quickly which criterion is being addressed.

Engage with other SOPs and ICD coding. Where a claimed factor is identified by an ICD code, include a clinician’s note explaining how the ICD classification maps to the SOP’s statutory definition. Rely on the SOP’s defined meaning rather than the code alone (s 7(3)-(4)).

Anticipate challenges to evidence sufficiency. Given the SOP’s precise thresholds, anticipate that decision-makers will challenge unsupported or vague assertions. Obtain objective, contemporaneous tests and clinician statements rather than retrospective or lay statements where possible. Where objective data are not available, an expert clinician should explain why the absence of records does not preclude application of a factor.

Prepare for administrative linkage obligations. Because the SOP requires that factors be "related to the relevant service" (s 10(1)), assemble direct links from service records to the clinical events,eg service medical entries showing relevant symptoms, in-theatre medical evacuations, or event reports that coincide with the exposure or onset windows.

Monitor amendment status. Verify which version of the SOP applied at the relevant time by checking the Legislation Register and the RMA series page, especially where amendments like the pack‑year definition (No. 94 of 2022) may change evidentiary thresholds (Endnote 3). Use the version that was in force at the time the relevant decision was made, or follow transitional rules where applicable.

Coordinate legal and clinical teams. Practitioners should coordinate lawyers and clinicians to ensure that medico-legal submissions align tightly with statutory wording: cross-reference the particular s 9 subsection relied upon, include Schedule 1 definitions and work through s 10 service-relationship requirements.

Document the causal chain for death claims. If death from RVO is alleged, prepare a causal narrative linking RVO to a terminal event listed in the Schedule with corroborating clinical and, where available, post-mortem evidence (s 7(5); Schedule 1 terminal event list).

In practice, compliance is about translating clinical history and tests into the statutory language of the SOP and proving the requisite temporal and service links. The SOP’s precise metrics and windows mean careful, contemporaneous documentation and targeted specialist opinion are the most effective compliance tools.